PLX · Protalix BioTherapeutics Inc
United States · RS rating 82 · As of 2026-10-14
| Price | 2.61 USD |
|---|---|
| 1-day change | -5.1% |
| RS rating (overall / 1M / 3M / 12M) | 82 / 53 / 87 / 56 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 36 / 51 / 19 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -77.3% |
| Sales growth Q/Q | -48.9% |
| Distance from 52-week high | +17.1% |
| Market cap (USD) | $172.4M |